Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

114.19
Delayed Data
As of Oct 20
 -0.08 / -0.07%
Today’s Change
83.01
Today|||52-Week Range
153.15
+13.88%
Year-to-Date
Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?
Oct 18 / Zacks.com - Paid Partner Content
5 Toxic Stocks to Abandon or Sell Short for Gains
Oct 12 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close114.27
Today’s open113.74
Day’s range112.71 - 114.39
Volume1,571,603
Average volume (3 months)1,498,418
Market cap$24.1B
Dividend yield--
Data as of 3:59pm ET, 10/20/2017

Growth & Valuation

Earnings growth (last year)+1,700.00%
Earnings growth (this year)-250.43%
Earnings growth (next 5 years)+92.90%
Revenue growth (last year)+46.70%
P/E ratioNM
Price/Sales17.60
Price/Book51.41

Competitors

 Today’s
change
Today’s
% change
ZTSZoetis Inc+0.36+0.55%
ALXNAlexion Pharmaceutic...-1.44-1.03%
BAXBaxter International...+0.12+0.19%
MYLMylan NV+0.22+0.57%
Data as of 4:14pm ET, 10/20/2017

Financials

Next reporting dateOctober 31, 2017
EPS forecast (this quarter)$0.05
Annual revenue (last year)$1.1B
Annual profit (last year)$104.2M
Net profit margin9.43%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts